Stone Pharmaceutical Group: The application for the listing of Pemtuzumab Monoimmunotoxin injection has been accepted by the National Medical Products Administration.

Shiyao Group Announcement: The subsidiary of our company, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has had its application for the listing of Pertuzumab Injection accepted by the National Medical Products Administration of the People's Republic of China. The product is classified as a type 3.3 therapeutic biological product, indicated for HER2-positive breast cancer.